Clinical Trials Arena
202 articles in the TruthFoundry index. Each links out to the original.
- Aravax's peanut allergy drug shows promise in pediatric trials · Aravax's PVX108 drug showed significant efficacy in pediatric peanut allergy patients during Phase II trials.
- Tirzepatide improves heart failure biomarkers presented at AHA 2026 · AHA 2026 presentation reports tirzepatide improves obesity-related heart failure biomarkers.
- Vivani reports positive Phase I results for semaglutide implant in weight management · Vivani Medical's Phase I trial of NPM-139, a subdermal semaglutide implant, shows 0.79% weight loss with no adverse events.
- Centessa executive outlines CRO selection for emerging biotechs · Scott Sawicki of Centessa explains CRO selection for biotechs starting clinical trials.
- Amgen's Sjögren's drug shows Phase III success, outperforms Novartis' candidate · Amgen's dazodalipeb demonstrated efficacy in Sjögren's disease Phase III trials, surpassing Novartis' ianalumab in systemic disease activity improvement.
- Actinium Pharmaceuticals opens enrolment for RADIANZ solid tumour trial · Actinium Pharmaceuticals has commenced patient enrolment for its RADIANZ solid tumour imaging trial.
- Orforglipron Outperforms Oral Semaglutide in Cardiovascular Risk Reduction at AHA26 · AHA26 study reveals Orforglipron surpasses oral semaglutide in predicted cardiovascular risk reduction.
- Lung cancer risk prediction requires more than age and smoking history · Lung cancer risk assessment extends beyond age and smoking history factors.
- WHO adds two Ebola vaccines to ongoing Tumaini clinical trial in DRC · WHO will add ChAdOx1 and mRNA-1469 vaccines to the Bundibugyo Ebola trial in DRC
- Gilead seeks Livdelzi label expansion after positive Phase III liver trial results · Gilead Sciences reports successful Phase III IDEAL trial results for PBC drug Livdelzi.
- UK clinical trial recruitment falls fifth year as China leads globally · ABPI report finds UK clinical trial enrolment dropped for the fifth consecutive year.
- Intellia completes enrolment for Phase III ATTRv-PN CRISPR therapy trial · Intellia Therapeutics has finished patient enrolment for its Phase III MAGNITUDE-2 clinical trial.
- Tango and Erasca open enrolment for Phase I/II ERAS-0015 cancer trial · Tango Therapeutics and Erasca launch patient enrolment for a combined oncology drug trial.
- UK MHRA pilot finds early trial inclusion plans benefit commercial sponsors · UK regulatory pilot found early clinical trial inclusion plans benefit commercial sponsors most.
- National Diabetes Month referenced in Clinical Trials Arena promotion · Clinical Trials Arena advertises free premium access alongside National Diabetes Month
- Signant Health launches SignalSpace integrated clinical trial platform · Signant Health releases SignalSpace, a unified platform for clinical trial data and workflows.
- Merck launches Phase III ENHANCE-3 trial for COPD drug Ohtuvayre · Merck has initiated the Phase III ENHANCE-3 clinical trial for COPD treatment Ohtuvayre.
- FDA places partial hold on Bright Minds Phase II seizure drug trial · Bright Minds Biosciences stock fell 52% after FDA issued partial trial hold
- Abbott Amulet 360 shows strong one-year AFib patient trial outcomes · Abbott's Amulet 360 occluder achieved 96.3% LAA closure in one-year VERITAS trial.
- Tiziana foralumab Phase IIa trial meets dual endpoints for na-SPMS · Tiziana Life Sciences reports its foralumab Phase IIa trial met primary endpoints for na-SPMS.
- Teva halts Phase II MSA therapy trial after futility analysis · Teva Pharmaceuticals will stop its Phase II trial for emrusolmin MSA treatment.
- Pretzel Therapeutics secures UK approval for PX578 mitochondrial disorder trial · Pretzel Therapeutics receives UK MHRA authorisation for Phase II PX578 clinical trial.
- IQVIA Executives Propose AI To Accelerate Clinical Trial Contract Negotiations · IQVIA leaders outline connected AI systems to reduce clinical trial contracting delays.
- AstraZeneca terminates late-stage Ultomiris kidney transplant trial · AstraZeneca cancels Phase III AWAKE Ultomiris trial following poor efficacy projections.
- Starton partners with Stanford for STAR-LLD multiple myeloma clinical trial · Starton Therapeutics and Stanford Medicine will test STAR-LLD CAR-T combination for multiple myeloma.
- Clinical Trials Arena offers free premium content via account registration · Clinical Trials Arena gates premium content behind free user profile registration
- ESMO 2026 Congress podcast covers oncology study results and themes · Clinical Trials Arena publishes podcast reviewing 2026 ESMO Congress outcomes from Madrid.
- Eli Lilly retatrutide outperforms Ozempic in head-to-head Phase III trial · Eli Lilly's retatrutide delivered double the weight loss of Ozempic in published trial results.
- IDWeek 2026: BNT163 targets unmet genital herpes medical need · BNT163 is positioned to address unmet genital herpes need at IDWeek 2026.
- FDA oncology trial reforms evaluated at ESMO 2026 Congress · Former FDA oncology director assesses US clinical trial regulatory changes at ESMO 2026.